The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer

dc.contributor.authorGungor, Hilal
dc.contributor.authorIlhan, Nevin
dc.contributor.authorEroksuz, Hatice
dc.date.accessioned2026-08-12T16:41:21Z
dc.date.issued2018
dc.departmentFırat Üniversitesi
dc.description.abstractColorectal cancer (CRC) is an important cause of cancer-related deaths worldwide. Early diagnosis and treatment of CRCs are of importance for improving the survival. In the present study, we studied the effects of nonsteroidal anti-inflammatory drugs (NSAIDs)-induced chemopreventive effects on tumor development incidence and angiogenesis in experimental CRC rats. 1,2-Dimethylhydrazine dihydrochloride (DMH) was used as cancer-inducing agent and two NSAIDs (celecoxib and diclofenac) were given orally as chemopreventive agents. Histopathological and immuno histochemical evaluations were performed in colorectal tissue samples, whereas angiogenesis parameters were studied in blood samples. Histopathological examination showed that adenocarcinoma (62.5%), dysplastic changes (31.25%) and inflammattory changes (6.25%) were detected in DMH group, whereas no pathological change was observed in control rats. In treatment groups, there was marked decrease in adenocarcinoma rate (30% and 10%, respectively). A significant increase was detected in MMP-2, MMP-9 levels and MMP-2/ TIMP-2 ratio in DMH group as compared with controls and treatment groups. In immunohistochemical evaluations, there was an increase in intensity and extent of staining of MMP-2 and MMP9 in DMH group as compared to controls and treatment groups. The decrease in celecoxib group was more prominent. Overall, it was concluded that NSAIDs, particularly cyclooxygenase-2 (COX-2) inhibitors, might have a protective effect on CRC development and slow down progression of tumor in a DMH-induced experimental cancer model. One of the possible mechanisms in the chemoprevention of colon cancer seems to be inhibition of angiogenesis by diclofenac and celecoxib.
dc.identifier.doi10.1016/j.biopha.2018.03.066
dc.identifier.endpage229
dc.identifier.issn0753-3322
dc.identifier.issn1950-6007
dc.identifier.orcid0000-0002-0208-8929
dc.identifier.pmid29562216
dc.identifier.scopus2-s2.0-85043994097
dc.identifier.scopusqualityQ1
dc.identifier.startpage221
dc.identifier.urihttps://doi.org/10.1016/j.biopha.2018.03.066
dc.identifier.urihttps://hdl.handle.net/11508/45798
dc.identifier.volume102
dc.identifier.wosWOS:000432583800027
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier France-Editions Scientifiques Medicales Elsevier
dc.relation.ispartofBiomedicine & Pharmacotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectAngiogenesis
dc.subjectColorectal cancer
dc.subjectCOX-2 inhibitors
dc.subjectNSAI drugs
dc.titleThe effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer
dc.typeArticle

Dosyalar